These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 1282792

  • 1. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
    Larder BA.
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2664-9. PubMed ID: 1282792
    [Abstract] [Full Text] [Related]

  • 2. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M, Kemp SD, Parry NR, Larder BA.
    Proc Natl Acad Sci U S A; 1993 Jun 15; 90(12):5653-6. PubMed ID: 7685907
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
    Balzarini J, Pelemans H, Riess G, Roesner M, Winkler I, De Clercq E, Kleim JP.
    Biochem Pharmacol; 1998 Mar 01; 55(5):617-25. PubMed ID: 9515572
    [Abstract] [Full Text] [Related]

  • 7. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
    de Vreese K, Debyser Z, Vandamme AM, Pauwels R, Desmyter J, de Clercq E, Anné J.
    Virology; 1992 Jun 01; 188(2):900-4. PubMed ID: 1374986
    [Abstract] [Full Text] [Related]

  • 8. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
    Balzarini J, Karlsson A, Pérez-Pérez MJ, Camarasa MJ, Tarpley WG, De Clercq E.
    J Virol; 1993 Sep 01; 67(9):5353-9. PubMed ID: 7688822
    [Abstract] [Full Text] [Related]

  • 9. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates.
    White EL, Buckheit RW, Ross LJ, Germany JM, Andries K, Pauwels R, Janssen PA, Shannon WM, Chirigos MA.
    Antiviral Res; 1991 Oct 01; 16(3):257-66. PubMed ID: 1725247
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
    Bazmi HZ, Hammond JL, Cavalcanti SC, Chu CK, Schinazi RF, Mellors JW.
    Antimicrob Agents Chemother; 2000 Jul 01; 44(7):1783-8. PubMed ID: 10858331
    [Abstract] [Full Text] [Related]

  • 13. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 14. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.
    Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J.
    Proc Natl Acad Sci U S A; 1991 Dec 15; 88(24):11241-5. PubMed ID: 1722324
    [Abstract] [Full Text] [Related]

  • 15. Biochemical and genetical analysis of AZT-resistant HIV-mutants.
    Biesert L, Zimmermann F, Schröder B, Matthes E, Suhartono H, Dietrich U, Rübsamen-Waigmann H.
    Behring Inst Mitt; 1991 Jul 15; (89):74-80. PubMed ID: 1930105
    [Abstract] [Full Text] [Related]

  • 16. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
    Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D.
    J Virol; 1994 Mar 15; 68(3):1660-6. PubMed ID: 7509000
    [Abstract] [Full Text] [Related]

  • 17. Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines.
    Nguyen MH, Schinazi RF, Shi C, Goudgaon NM, McKenna PM, Mellors JW.
    Antimicrob Agents Chemother; 1994 Oct 15; 38(10):2409-14. PubMed ID: 7840579
    [Abstract] [Full Text] [Related]

  • 18. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
    Nájera I, Richman DD, Olivares I, Rojas JM, Peinado MA, Perucho M, Nájera R, López-Galíndez C.
    AIDS Res Hum Retroviruses; 1994 Nov 15; 10(11):1479-88. PubMed ID: 7534096
    [Abstract] [Full Text] [Related]

  • 19. Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors.
    Taylor PB, Culp JS, Debouck C, Johnson RK, Patil AD, Woolf DJ, Brooks I, Hertzberg RP.
    J Biol Chem; 1994 Mar 04; 269(9):6325-31. PubMed ID: 7509800
    [Abstract] [Full Text] [Related]

  • 20. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
    Debyser Z, Vandamme AM, Pauwels R, Baba M, Desmyter J, De Clercq E.
    J Biol Chem; 1992 Jun 15; 267(17):11769-76. PubMed ID: 1376311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.